Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (171-180 of 242) with videos related to

Pageof 25
Sort By:
Clinical Lung Cancer|June 5, 2018
A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study ProtocolYoshihito Kogure, Hideo Saka, Yuichi Takiguchi, et al.
Cancer Science|January 9, 2019
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancerMakoto Nishio, Toshiaki Takahashi, Hiroshige Yoshioka, et al.
The Lancet. Oncology|September 2, 2014
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyTakashi Seto, Terufumi Kato, Makoto Nishio, et al.
BMC Pharmacology & Toxicology|October 7, 2020
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational studyReiko Matsui, Kenichi Suzuki, Tomomi Takiguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung CancerKazuhiko Nakagawa, Ernest Nadal, Edward B Garon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2017
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JPTomohide Tamura, Katsuyuki Kiura, Takashi Seto, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)Minoru Fukuda, Takeshi Kitazaki, Daiki Ogawara, et al.
Lung Cancer (Amsterdam, Netherlands)|October 31, 2016
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective studyKaname Nosaki, Miyako Satouchi, Takayasu Kurata, et al.
JTO Clinical and Research Reports|April 6, 2026
Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia RegistryShingo Matsumoto, Takashi Seto, Christer Svedman, et al.
The Lancet. Respiratory Medicine|November 10, 2016
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trialKiyotaka Yoh, Takashi Seto, Miyako Satouchi, et al.
Pageof 25

Showing results (171-180 of 242) with videos related to

Sort By:
Pageof 25
Clinical Lung Cancer|June 5, 2018
A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study ProtocolYoshihito Kogure, Hideo Saka, Yuichi Takiguchi, et al.
Cancer Science|January 9, 2019
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancerMakoto Nishio, Toshiaki Takahashi, Hiroshige Yoshioka, et al.
The Lancet. Oncology|September 2, 2014
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyTakashi Seto, Terufumi Kato, Makoto Nishio, et al.
BMC Pharmacology & Toxicology|October 7, 2020
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational studyReiko Matsui, Kenichi Suzuki, Tomomi Takiguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung CancerKazuhiko Nakagawa, Ernest Nadal, Edward B Garon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2017
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JPTomohide Tamura, Katsuyuki Kiura, Takashi Seto, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)Minoru Fukuda, Takeshi Kitazaki, Daiki Ogawara, et al.
Lung Cancer (Amsterdam, Netherlands)|October 31, 2016
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective studyKaname Nosaki, Miyako Satouchi, Takayasu Kurata, et al.
JTO Clinical and Research Reports|April 6, 2026
Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia RegistryShingo Matsumoto, Takashi Seto, Christer Svedman, et al.
The Lancet. Respiratory Medicine|November 10, 2016
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trialKiyotaka Yoh, Takashi Seto, Miyako Satouchi, et al.
Pageof 25